Network pharmacology: the next paradigm in drug discovery (Q28297997)

Can the pharmaceutical industry reduce attrition rates?

Europe PubMed Central

title

Network pharmacology: the next paradigm in drug discovery (English)

0 references

0 references

1 reference

Andrew L Hopkins

1

0 references

language of work or name

English

0 references

publication date

November 2008

0 references

published in

Nature Chemical Biology

0 references

volume

4

0 references

page(s)

682-90

0 references

issue

11

0 references

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Target-based drug discovery: is something wrong?

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Paul Ehrlich: founder of chemotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Functional profiling of the Saccharomyces cerevisiae genome

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Mechanisms of haploinsufficiency revealed by genome-wide profiling in yeast

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

1 reference

7 January 2021

The knockout mouse project

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Predicting drug efficacy: knockouts model pipeline drugs of the pharmaceutical industry

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Knockouts model the 100 best-selling drugs--will they model the next 100?

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Towards a theory of biological robustness

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Network biology: understanding the cell's functional organization

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Error and attack tolerance of complex networks

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Variations in DNA elucidate molecular networks that cause disease

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

The efficiency of multi-target drugs: the network approach might help drug design

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

How to design multi-target drugs.

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Global synthetic-lethality analysis and yeast functional profiling

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

The chemical genomic portrait of yeast: uncovering a phenotype for all genes

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Multitargeted drugs: the end of the "one-target-one-disease" philosophy?

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Multicomponent therapeutics for networked systems

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Promiscuous drugs compared to selective drugs (promiscuity can be a virtue)

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Can we rationally design promiscuous drugs?

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Rethinking target discovery in polygenic diseases.

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Towards drugs targeting multiple proteins in a systems biology approach

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Multi-target therapeutics: when the whole is greater than the sum of the parts

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

The concept of synthetic lethality in the context of anticancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs.

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Synthetic lethal screen identification of chemosensitizer loci in cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Mediators of vascular remodelling co-opted for sequential steps in lung metastasis.

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

A robustness-based approach to systems-oriented drug design.

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Can intellectualism stifle scientific discovery?

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Targeting the cell cycle: a new approach to cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

When will the genomics investment pay off for antibacterial discovery?

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Use of genomics to select antibacterial targets

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Drugs for bad bugs: confronting the challenges of antibacterial discovery

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

The targets of currently used antibacterial agents: lessons for drug discovery

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Rational design of cancer-drug combinations

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Optimizing combination chemotherapy by controlling drug ratios

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Strategies for optimizing combinations of molecularly targeted anticancer agents

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Systematic discovery of multicomponent therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Optimal drug cocktail design: methods for targeting molecular ensembles and insights from theoretical model systems

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Knowledge discovery by automated identification and ranking of implicit relationships

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Conceptual biology, hypothesis discovery, and text mining: Swanson's legacy

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

High-throughput electronic biology: mining information for drug discovery

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Here is the evidence, now what is the hypothesis? The complementary roles of inductive and hypothesis-driven science in the post-genomic era

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Vulnerability and protection of infrastructure networks

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Lethality and centrality in protein networks

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Gene essentiality and the topology of protein interaction networks.

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

The importance of bottlenecks in protein networks: correlation with gene essentiality and expression dynamics

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

CYP3A5 genotype has no impact on plasma trough concentrations of lopinavir and ritonavir in HIV-infected subjects.

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Comparative genomics of centrality and essentiality in three eukaryotic protein-interaction networks

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Evidence for dynamically organized modularity in the yeast protein-protein interaction network

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

1 reference

7 January 2021

A global view of drug-therapy interactions

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Range-based attack on links in scale-free networks: Are long-range links responsible for the small-world phenomenon?

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

In vivo robustness analysis of cell division cycle genes in Saccharomyces cerevisiae

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Using the topology of metabolic networks to predict viability of mutant strains

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Logic models of pathway biology

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Drug-efficacy depends on the inhibitor type and the target position in a metabolic network--a systematic study.

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

The pairwise disconnectivity index as a new metric for the topological analysis of regulatory networks.

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Multiple weak hits confuse complex systems: a transcriptional regulatory network as an example.

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Predicting synthetic rescues in metabolic networks

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

The influence of drug-like concepts on decision-making in medicinal chemistry.

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

From magic bullets to designed multiple ligands

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

The physicochemical challenges of designing multiple ligands

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Molecular complexity and its impact on the probability of finding leads for drug discovery

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Fragment screening: an introduction

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Ligand efficiency: a useful metric for lead selection

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Fragments, network biology and designing multiple ligands

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

SPR-based fragment screening: advantages and applications

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Label-free primary screening and affinity ranking of fragment libraries using parallel analysis of protein panels

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Global mapping of pharmacological space

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Selective optimization of side activities: another way for drug discovery

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Selective optimization of side activities: the SOSA approach

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Distribution patterns of small-molecule ligands in the protein universe and implications for origin of life and drug discovery

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Binding similarity network of ligand.

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

STITCH: interaction networks of chemicals and proteins

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

SuperTarget and Matador: resources for exploring drug-target relationships

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Drug-therapy networks and the prediction of novel drug targets

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

From molecular to biological structure and back

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Relating protein pharmacology by ligand chemistry

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Quantifying the relationships among drug classes

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Prediction of drug-target interaction networks from the integration of chemical and genomic spaces.

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Large-scale prediction of drug-target relationships

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Drug target identification using side-effect similarity

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Probabilistic prediction and ranking of human protein-protein interactions

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Biospectra analysis: model proteome characterizations for linking molecular structure and biological response

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

The Poisson Index: a new probabilistic model for protein ligand binding site similarity.

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

A common reference framework for analyzing/comparing proteins and ligands. Fingerprints for Ligands and Proteins (FLAP): theory and application.

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Turning promiscuous kinase inhibitors into safer drugs

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Kinase-likeness and kinase-privileged fragments: toward virtual polypharmacology

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Novel paradigms for drug discovery: computational multitarget screening

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

How many drug targets are there?

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

A small molecule-kinase interaction map for clinical kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Cytoscape: a software environment for integrated models of biomolecular interaction networks

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO.118

7 January 2021

Identifiers

DOI

10.1038/NCHEMBIO.118

1 reference

Consolidated OpenCitations Corpus – April 2017

release_6tvdu3ms2nhjzp2g64rpdrxlea

455905

Fatcat ID

0 references

455905

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference